Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
03 September 2024
Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
22 July 2024
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
17 May 2024
Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges
14 May 2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
06 May 2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
22 April 2024
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
18 March 2024